Table 4.
Treatment adverse events of molecular targeted agents in Group A
| Adverse events | n (%) | |||
|---|---|---|---|---|
| Any grade | Grade 1 | Grade 2 | Grade 3 | |
| Hypertension | 10 (23.8) | 2 (4.8) | 6 (14.3) | 2 (4.8) |
| Palmar-plantar erythrodysaesthesia | 12 (28.6) | 9 (21.4) | 2 (4.8) | 1 (2.4) |
| Fatigue | 16 (38.1) | 8 (19.0) | 6 (14.3) | 2 (4.8) |
| Decreased appetite | 12 (28.6) | 7 (16.7) | 4 (9.5) | 1 (2.4) |
| Diarrhoea | 4 (9.5) | 3 (7.1) | 1 (2.4) | 0 |
Notes: Data are the number of patients, with percentages in parentheses; Group A, TIPS plus sequential systemic therapy. Adverse events grade 4 or 5 were not observed